Britain snubs costly Novartis blood cancer drug

British health authorities said on Wednesday they would not recommend Jakavi, a drug produced by Swiss pharmaceutical company Novartis to treat a rare form of blood cancer, deeming it too expensive.

Jakavi, or Ruxolitinib, was "clinically effective but could not be considered a cost-effective use of (the National Health Services') resources," the National Institute for Health and Clinical Excellence (NICE) said in a statement.

The drug is used to treat myelofibrosis, a rare type of or .

While NICE concluded that Ruxolitinib effectively treated symptoms and "could offer survival benefit," it lamented that it was simply too expensive to impose on the , since it would mean diverting costs from elsewhere.

"It is disappointing not to be able to recommend this new treatment in our preliminary recommendations," it said.

Novartis, which is facing a wave of expiring patents on its traditional big-sellers, is working hard to multiply its new drug offerings like Javaki to ensure continued growth.

But like the rest of the pharmaceutical industry, the company has also had to deal with growing pricing pressure at a time when crisis-hit countries are increasingly being forced to slash .

Last month it announced that its net sales in 2012 had slipped 3.0 percent year-on-year to $56.7 billion (42.1 million euros).

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments